摘要
作为针对恶性肿瘤的有效治疗方式,化疗已被广泛用于治疗各种恶性肿瘤。虽然化学治疗提高了患者的存活率及预后水平,但肿瘤迅速形成的多药耐药会导致治疗失败。近年发现,作为促多药耐药基因的lncRNA UCA1介导多种肿瘤形成耐药。该文回顾了UCA1在肿瘤耐药中的研究进展,并展望了该领域未来的发展及面临的挑战。
As an efficient treatment for malignant tumor,chemotherapy has been used widely in treating various tumors.Although the use of chemotherapy drugs has significantly improved patients’survival rate and prognosis,the rapid development of multidrug resistance will lead to therapeutic failure.In the past few years,lncRNA UCA1,as a multi-drug resistance gene,has been found to mediate drug resistance in a great number of tumors.This manuscript reviews the progress of UCA1 in drug resistance and prospects the development and challenge in the future.
作者
郑斌
王宇
ZHENG Bin;WANG Yu(The Second Clinical Medical College of Shaanxi University of Chinese Medicine,Xianyang 712046,China;Medical Research and Experiment Center,Shaanxi University of Chinese Medicine,Xianyang 712046,China)
出处
《中国细胞生物学学报》
CAS
CSCD
2020年第2期369-378,共10页
Chinese Journal of Cell Biology
基金
国家自然科学基金(批准号:81402344)
陕西省青年科技新星项目(批准号:2018KJXX-096)
陕西省自然科学基础研究计划(批准号:2015JQ8308)
陕西省教育厅科学研究计划(自然科学专项)(批准号:16JK1221)资助的课题。
